https://orcid.org/0000-0001-9369-8628
References
- Pfister C, Gravis G, Flechon A, VESPER Trial Investigators, et al. Dose-Dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER trial. J Clin Oncol. 2022;40(18):2013–2022.
- NUCOG (Nordic Urothelial Cancer Oncology Group). Available from: https://www.rigshospitalet.dk/nucog.
- Holmsten K, Omland LH, Als AB, et al. Implications for efficacy and safety of total dose and dose-intensity of neoadjuvant gemcitabine-cisplatin in muscle-invasive bladder cancer: three-week versus four-week regimen. BLC. 2022;8(1):71–80.
- Kim JK, Park SY, Ahn HJ, et al. Bladder cancer: analysis of multi-detector row helical CT enhancement pattern and accuracy in tumor detection and perivesical staging. Radiology. 2004;231(3):725–731.
- Girard A, Rouanne M, Taconet S, et al. Integrated analysis of (18)F-FDG PET/CT improves preoperative lymph node staging for patients with invasive bladder cancer. Eur Radiol. 2019;29(8):4286–4293.
- Fairey AS, Daneshmand S, Quinn D, et al. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the university of Southern California. Urol Oncol. 2013;31(8):1737–1743.
- Zargar H, Espiritu PN, Fairey AS, et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2015;67(2):241–249.
- Zeng S, Zhang Z, Xu C. Dose-Dense methotrexate, vinblastine, doxorubicin, and cisplatin as the gold standard neoadjuvant chemotherapy regimen for patients with nonmetastatic muscle-invasive bladder cancer remains controversial. J Clin Oncol. 2022;40(26):3093–3094.
- Pfister C, Harter V, Allory Y, et al. Reply to S. Zeng et al. J Clin Oncol. 2022;40(26):3094–3095.
- Choueiri TK, Jacobus S, Bellmunt J, et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014;32(18):1889–1894.
- von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068–3077.
- Sternberg CN, de Mulder PH, Schornagel JH, European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: european organization for research and treatment of cancer protocol no. 30924. J Clin Oncol. 2001;19(10):2638–2646.
- Omland LH, Lindberg H, Carus A, et al. Real-world treatment patterns and overall survival in locally advanced and metastatic urothelial tract cancer patients treated with chemotherapy in Denmark in the preimmunotherapy era: a nationwide, population-based study. Eur Urol Open Sci. 2021;24:1–8.
- Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med. 2021;384(22):2102–2114.